HBIO FINANCIAL STATEMENTS

Harvard Bioscience Inc — balance sheet, income statement and cash flow trends

HBIOHarvard Bioscience Inc

🇺🇸 USA · NASDAQ · Healthcare · Medical Instruments & Supplies

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue85.5 M $-6.4%

Gross Profit48.8 M $-6.5%

Operating Income1.2 M $—

EBITDA-1.9 M $—

Net Income-9.8 M $—

Peer Comparison· Medical Instruments & Supplies

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
HBIO	-6.4%	57.1%	-2.2%	-11.4%
SEYKM	-24.8%	29.7%	0.6%	1.3%
CTEC	6.8%	55.8%	25.3%	7.2%
Industry median	6.4%	53.7%	13.8%	3.9%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
HBIO	-6.4%	57.1%	-2.2%	-11.4%
EMBC	-3.4%	62.5%	30.9%	10.7%
KRMD	23.3%	61.5%	-3.4%	-5.3%
SMTI	17.4%	91.2%	7.7%	-31.2%
UTMD	-4.4%	53.6%	43.6%	28.9%
Industry median	6.4%	53.7%	13.8%	3.9%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity10 M $13%
Current Liabilities23.9 M $31%
Long-term Liabilities44 M $56%

Key Figures

YoY change

Total Assets77.9 M $-2.3%

Total Liabilities67.9 M $+4.5%

Total Equity10 M $-32.3%

Cash & ST Investments7.1 M $+28.0%

Total Debt44.1 M $-1.1%

Net Debt37 M $-5.2%

Peer Comparison· Medical Instruments & Supplies

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
HBIO	1.99	439.2%	-19.80	12.9%
SEYKM	6.82	0.0%	-168.37	88.1%
CTEC	1.53	100.0%	2.33	40.1%
Industry median	2.40	34.8%	1.44	62.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
HBIO	1.99	439.2%	-19.80	12.9%
EMBC	2.46	-216.9%	3.64	-60.8%
KRMD	2.33	19.9%	3.68	59.2%
SMTI	2.28	688.1%	4.17	10.1%
UTMD	28.64	0.2%	-5.33	96.8%
Industry median	2.40	34.8%	1.44	62.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow3.1 M $+1.9%

Capital Expenditures1.6 M $-47.8%

Free Cash Flow1.5 M $—

Dividends Paid——

Peer Comparison· Medical Instruments & Supplies

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
HBIO	3.6%	1.7%	1.9%	-31.5%
SEYKM	33.6%	46.3%	3.1%	2,535.7%
CTEC	19.1%	14.1%	4.9%	265.8%
Industry median	13.8%	8.6%	3.8%	128.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on HBIO

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.